In the Claims:

Please cancel claims 6-15, without disclaimer or prejudice to the inclusion of the subject matter contained therein in any later filed continuation or divisional application(s). Further, please add new claims 16-31.

Claims 1-15 (Canceled)

- 16. (New) A method of identifying a protein, a polypeptide or a peptide secreted from a human adipocyte comprising
 - a) isolating human preadipocytes;
- b) differentiating said human preadipocytes with a differentiation medium comprising a defined cell culture medium; wherein said medium comprises 1.0-4.5 g/liter glucose, a cyclic AMP inducer, a glucocorticoid or a glucocoticoid analogue, insulin or an insulin analogue, and a Peroxisome Proliferator Activated Receptor gamma agonist or a retinoic acid X receptor agonist effective to stimulate differentiation of said human preadipocytes;
- c) comparing the pattern of proteins, polypeptides or peptides secreted by the differentiated cell with the pattern of proteins, polypeptides or peptides secreted by an undifferentiated adipocyte;
- d) identifying the proteins, polypeptides or peptides secreted by the differentiated cell.
- 17. (New) The method of claim 16, wherein said medium further comprise 3-10% fetal bovine serum.
- 18. (New) The method of claim 16, wherein said medium further comprise 1-100 μ M pantothenate and 1-100 μ M biotin.
- 19. (New) The method of claim 16, wherein said medium further comprises a buffer having a pH of about 7.0 to 7.6.

- 20. (New) The method of claim 16, wherein said medium is Dulbeccos Modified Eagle/Hams' F-10 Nutrient Broth (1:1 vol/vol).
- 21. (New) The method of claim 16, wherein said Peroxisome Proliferator Activated Receptor gamma agonist is thiazolidinedione.
- 22. (New) The method of claim 21, wherein said thiazolidinedione is BRL 49653.
- 23. (New) The method of claim 22, wherein the concentration of said BRL 49653 is about 0.5-1.0 μ M.
 - 24. (New) The method of claim 21 wherein said thiazolidinedione is troglitazone.
- 25. (New) The method of claim 24, wherein the concentration of said troglitazone is about 0.5-1.0 μM .
- 26. (New) The method of claim 16, wherein said glucocorticoid is dexamethasone, hydrocortisone or cortisol.
- 27. (New) The method of claim 26, wherein the concentration of said glucocorticoid is about 16 nM to 1.0 μ M.
- 28. (New) The method of claim 16, wherein said cyclic AMP inducer is isobutylmethylxanthine or forskolin.
- 29. (New) The method of claim 28, wherein said isobutylmethylxanthine is present in said medium at a final concentration of about 0.2 to 0.5 mM.
- 30. (New) The method of claim 16, wherein the concentration of insulin is about 100 nM to 1.0 μM .

31. (New) The method of claim 16, wherein said preadipocyte is genetically modified.